These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11361607)

  • 1. DaunoXome approved.
    AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361607
    [No Abstract]   [Full Text] [Related]  

  • 2. Kaposi's sarcoma: DaunoXome approved.
    AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract]   [Full Text] [Related]  

  • 4. [New data: daunoxome against Kaposi sarcoma. Fifth European Conference on clinical aspects and treatment of HIV infection].
    Pharm Unserer Zeit; 1996 Jan; 25(1):42-3. PubMed ID: 8882752
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
    J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50-1. PubMed ID: 11363534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal KS drugs approved.
    GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal doxorubicin.
    Linsky KF; Ignoffo RJ
    Cancer Pract; 1996; 4(5):288-90. PubMed ID: 9004577
    [No Abstract]   [Full Text] [Related]  

  • 9. DOXIL approved by FDA.
    AIDS Patient Care; 1995 Dec; 9(6):306. PubMed ID: 11361446
    [No Abstract]   [Full Text] [Related]  

  • 10. DaunoXome data presented at international cancer meeting.
    Oncology (Williston Park); 1996 Jun; 10(6):830. PubMed ID: 8823798
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
    Wernz JC
    AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
    [No Abstract]   [Full Text] [Related]  

  • 12. KS treatment inches forward.
    Vazquez E
    Posit Aware; 1996; 7(5):9. PubMed ID: 11363790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DaunoXome offers KS treatment alternative.
    AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
    AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
    Chew T; Jacobs M
    Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
    Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NeXstar Pharmaceuticals lauches DaunoXome.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):52. PubMed ID: 11363700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
    Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
    AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
    Loke WC; Spittle MF; Mitchell S; Kulasegaram R
    Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
    Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.